LATEST TWEETS - CURATED BY HASH FINANCE

$OMER one more day closer to BLA and narsoplimab approval. Dr. Greg’s guidance has been 100% accurate so far. In Dr.Greg we trust
-$0.38 Earnings Per Share Expected for Omeros Co. $OMER This Quarter https://t.co/tOlK7c6136 #stocks
Tickeron (Tickeron) 3 hours ago
$OMER in Uptrend: Stochastic indicator leaves oversold zone. View odds for this and other indicators:… https://t.co/tWaU4Z73J9
$OMER Options Synthetic Long Market in 21-Feb-20 19 Strike is Priced at a -2.0% Discount to Spot(18.70 vs 19.09) https://t.co/3auehn5R5u
$OMER #Omeros Safety and Tolerability Demonstrated in OMS527 Phase 1 Study for Addiction: | https://t.co/dkyi65XrZN https://t.co/tvWLSi4xzs
Tickeron (Tickeron) 1 day ago
$OMER's price moved above its 50-day Moving Average on August 8, 2019. View odds for this and other indicators:… https://t.co/HVHJmKs7j2
Jensen (Jensen881) 1 day ago
Congrats! Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Developmen… https://t.co/BqM92EH6Il
Recent $OMER technical alerts: 180 Bullish Setup plus 2 more alerts... https://t.co/zRCcYHccnL
$OMER - Omeros up 2% on favorable safety data on addiction candidate https://t.co/t7WkSa2fqQ
$OMER: Omeros announces "positive" results from Phase 1 study of PDE7 inhibitor in development as treatment for... https://t.co/U4Q9gB3fFf
$OMER: Omeros Corporation Announces Positive Results from Phase 1 …: https://t.co/WaQPwANiXZ
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addic https://t.co/MFUIzCQ7aJ
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addi… https://t.co/76CuqB10mr
Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development for Addi… https://t.co/EJhc4iD5gb
$OMER : Omeros Corporation Announces Positive Results from Phase 1 Study of its Lead PDE7 Inhibitor in Development… https://t.co/bS9GkzfFTR
@PersimmonTI Narso BLA being submitted mid Q4. OMIDRIA revenue growing at a rate of 15% or more a quarter. And then… https://t.co/hzUkmv7Bdn
Contrasting Respirerx Pharmaceuticals $RSPI and Omeros $OMER https://t.co/Mab4L7gXi8
Omeros $OMER Cut to Hold at BidaskClub https://t.co/h0WmgGiN8m
Tickeron (Tickeron) 4 days ago
$OMER's price moved above its 50-day Moving Average on August 8, 2019. View odds for this and other indicators:… https://t.co/hvltj0AQwJ
Omeros $OMER Cut to Hold at BidaskClub https://t.co/MFeWe7OqUY
Buy! Sell! No buy! On second thought, sell! Actually just leave your human husband for Omeros $OMER #wealth
Tickeron (Tickeron) 5 days ago
$OMER in Uptrend: 50-day Moving Average crossed above 200-day Moving Average on May 1, 2019. View odds for this and… https://t.co/YDpusQeqAi
ChartMill (ChartMill) 5 days ago
$OMER: The short term is neutral, but the long term trend is still positive. Not much to worry about for now.… https://t.co/90EcYVIdkl
BidaskClub Downgrades Omeros $OMER to Hold https://t.co/MGaxmRsEIi
Do you know that #Book Value for $OMER is $-2.65 https://t.co/16Z7kBm5zI
Lj💎 (TraderJill77) 5 days ago
I have long been a fan of Omeros - $OMER. They have a diverse pipeline, and one marketed blockbuster drug OMIDRIA.… https://t.co/AQA3kXTZKl